Published in Int J Cancer on April 15, 2006
Single cells and intracellular processes studied by a plasmonic-based electrochemical impedance microscopy. Nat Chem (2011) 2.33
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood (2007) 1.86
Inhibition of the ubiquitin-proteasome system induces stress granule formation. Mol Biol Cell (2007) 1.75
Therapy of human papillomavirus-related disease. Vaccine (2012) 1.11
The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium. Arch Otolaryngol Head Neck Surg (2007) 1.00
Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5. BMC Cancer (2011) 0.87
Complexes of human papillomavirus type 16 E6 proteins form pseudo-death-inducing signaling complex structures during tumor necrosis factor-mediated apoptosis. J Virol (2008) 0.82
RNA interference for the treatment of papillomavirus disease. Open Virol J (2012) 0.80
Cellular DNA repair cofactors affecting hepatitis B virus infection and replication. World J Gastroenterol (2008) 0.77
Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism. Cell Death Dis (2014) 0.77
Nip the HPV encoded evil in the cancer bud: HPV reshapes TRAILs and signaling landscapes. Cancer Cell Int (2013) 0.75
Proteasomal inhibition sensitizes cervical cancer cells to mitomycin C-induced bystander effect: the role of tumor microenvironment. Cell Death Dis (2015) 0.75
Enhanced efficacy against cervical carcinomas through polymeric micelles physically incorporating the proteasome inhibitor MG132. Cancer Sci (2016) 0.75
Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.55
Evidence based selection of housekeeping genes. PLoS One (2007) 7.90
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med (2011) 7.82
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med (2003) 3.15
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73
Metformin: taking away the candy for cancer? Eur J Cancer (2010) 2.68
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother (2008) 2.54
A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer (2012) 2.39
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol (2004) 2.32
Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet (2002) 2.17
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol (2005) 2.14
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med (2009) 2.12
Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol (2008) 2.03
Identification of a ubiquitin-protein ligase subunit within the CCR4-NOT transcription repressor complex. EMBO J (2002) 1.98
[Primary surgery by a gynecological oncologist improves the prognosis in patients with ovarian carcinoma]. Ned Tijdschr Geneeskd (2009) 1.97
TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev (2008) 1.94
Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med (2009) 1.88
Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res (2013) 1.87
Receptor conversion in distant breast cancer metastases. Breast Cancer Res (2010) 1.85
Three-dimensional conformal simultaneously integrated boost technique for breast-conserving radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.79
Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol (2006) 1.79
High-grade dysplasia in sporadic fundic gland polyps: a case report and review of the literature. Eur J Gastroenterol Hepatol (2003) 1.77
Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol (2008) 1.76
Plasma free metanephrine measurement using automated online solid-phase extraction HPLC tandem mass spectrometry. Clin Chem (2007) 1.74
Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res (2008) 1.70
Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med (2011) 1.62
The prognostic effect of the number of histologically examined axillary lymph nodes in breast cancer: stage migration or age association? Ann Surg Oncol (2006) 1.58
Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol (2006) 1.57
The insulin-like growth factor system and sarcomas. J Pathol (2009) 1.57
Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer (2006) 1.55
Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol (2010) 1.55
TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. Clin Cancer Res (2006) 1.52
Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. Oncogene (2004) 1.50
Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev (2002) 1.50
Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta (2009) 1.45
Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest (2010) 1.43
Intraoperative multispectral fluorescence imaging for the detection of the sentinel lymph node in cervical cancer: a novel concept. Mol Imaging Biol (2011) 1.41
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2011) 1.40
Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med (2007) 1.39
ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res (2005) 1.37
Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol (2003) 1.36
Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol (2003) 1.31
Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol (2004) 1.31
Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res (2003) 1.29
VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res (2010) 1.27
Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem (2004) 1.27
Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res (2007) 1.27
TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol (2009) 1.26
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer (2009) 1.26
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol (2007) 1.26
Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia (2008) 1.25
Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? Cancer Treat Rev (2004) 1.25
Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol (2005) 1.24
89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med (2010) 1.23
Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int J Cancer (2006) 1.23
ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol (2007) 1.21
Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol (2003) 1.17
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res (2009) 1.16
The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res (2003) 1.15
An oncological view on the blood-testis barrier. Lancet Oncol (2002) 1.15
The role of antibiotic prophylaxis in prevention of wound infection after Lichtenstein open mesh repair of primary inguinal hernia: a multicenter double-blind randomized controlled trial. Ann Surg (2004) 1.15
Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res (2011) 1.13
Effect of vemurafenib on a V600R melanoma brain metastasis. Eur J Cancer (2013) 1.13
Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat (2005) 1.13
Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET. Neuroimage (2003) 1.13
6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab (2009) 1.11
The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell Oncol (Dordr) (2011) 1.10
PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol (2013) 1.10
The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat (2007) 1.10
Translating TRAIL-receptor targeting agents to the clinic. Cancer Lett (2012) 1.10
PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med (2012) 1.10
Profiling studies in ovarian cancer: a review. Oncologist (2007) 1.09
Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol (2006) 1.08
Considerations on absence of 68Ga-DOTA-F(ab')2-trastuzumab tracer uptake in HER2-overexpressing tumor lesions. Nucl Med Commun (2014) 1.07
CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J Cancer (2013) 1.06
Variability in axillary lymph node dissection for breast cancer. J Surg Oncol (2004) 1.05
Detecting cervical cancer by quantitative promoter hypermethylation assay on cervical scrapings: a feasibility study. Mol Cancer Res (2004) 1.04
Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res (2009) 1.03
89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med (2013) 1.03